Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149520 (acute cholecystitis)
 2,784 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A new antibiotic drug of cephalosporin, with marked resistance to beta-lactamase, cefoperazone (CPZ) for parenteral use was used in 10 patients with acute cholecystitis or cholangitis with cholelithiasis. CPZ was given by drip intravenous injection at a daily dose of 1 to 4 g. Clinical response was excellent in 1 case, good in 7 cases, fair in 2 cases and poor was none. Clinical adverse effect was not recognized. And CPZ in a dose of 1 g was given intravenously during the operation to 6 of those patients. Tissue specimens of different sites were taken from removed organs. The materials of A-bile and B-bile were subsequently taken at intervals. Determination of CPZ concentration was performed according to paper disk method with Micrococcus luteus ATCC 9341 strain. CPZ concentrations in the A-bile increased quickly soon after injection, and reached high level peak at 30-min. to 1 hour, then they were very slow decline. CPZ was observed in the B-bile through the gallbladder wall, and reached high level concentration comparative quickly after intravenous injection. CPZ concentration in the gallbladder wall, was directly proportional to the degree of pathological changes of inflammation. On the CPZ concentration in patients with acute cholecystitis, the concentration in A-bile, B-bile and gallbladder wall were observed extremely higher than the MIC or CPZ for Escherichia coli. CPZ therefore will be a very useful drug when used for chemotherapy of biliary tract infection.
 ...
PMID:[Studies on cefoperazone concentration in human biliary tract and clinical effect for acute cholecystitis and cholangitis (author's transl)]. 645 12

A new antibiotic drug of oxacephem, with marked resistance to beta-lactamase, 6059-S for parenteral use was used in 12 patients with acute cholecystitis and cholangitis. 6059-S was given by intramuscular, intravenous or drip intravenous administration at a daily dose of 500 mg to 2 g. Clinical response was excellent in 1 case, good in 10 cases, fair in 1 case and poor in none. Any clinical adverse effect was not recognized. 6059-S is a dose of 500 mg was given by intramuscular administration before the operation to 9 patients. Tissue specimens of different sites were taken from removed organs. The materials of A-bile and B-bile were subsequently taken at intervals. 6059-S concentrations in the A-bile increased after injection and reached to peak from 2 hours to 2.5 hours, then declined very slowly. 6059-S concentration in the B-bile reached to high level of the concentration comparative quickly after intramuscular administration, and it was thought to be excreted through the wall of the gallbladder. 6059-S concentration in the gallbladder wall was directly proportional to the degree of pathological changes of inflammation. On the 6059-S concentration in patients with acute cholecystitis and cholangitis, the concentration in A-bile, B-bile and gallbladder wall were observed higher than the MIC of 6059-S for Escherichia coli and Klebsiella pneumoniae. Therefore 6059-S will be a very useful drug when used for chemotherapy of the infectious diseases of the biliary tract.
 ...
PMID:[Clinical studies on 6059-S for biliary tract diseases. Clinical effect and tissue concentration (author's transl)]. 645 72